* Pharvaris NV PHVS.OQ PHVS.O is expected to show no
change in
quarterly revenue when it reports results on November 8
(estimated).
*
* Refinitiv's mean analyst estimate for Pharvaris NV is for
a
loss of 64 cents per share.
* The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," 1
"hold" and 1 "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Pharvaris
NV is
$18, above its last closing price of $3.90.
Previous quarterly performance (using preferred earnings measure
in euros).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -0.57 -0.56 -0.38 Beat 31.7
Mar. 31 2022 -0.43 -0.47 -0.48 Missed -1.6
Dec. 31 2021 -0.99 -0.72 -0.09 Beat 87.6
Sep. 30 2021 -0.44 -0.44 -0.39 Beat 11.4
Jun. -0.39 -0.42 -0.94 Missed -122
30 2021
Mar. 31 2021 -0.34 -0.38 -0.66 Missed -72.5
Dec. 31 2020 -1.14 -1.14 -2.18 Missed -90.7
This summary was machine generated November 4 at 17:04 GMT. All
figures in euros unless otherwise stated